E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints

  1. Bing Ren1,4,5,
  2. Hieu Cam3,4,
  3. Yasuhiko Takahashi3,
  4. Thomas Volkert1,
  5. Jolyon Terragni1,
  6. Richard A. Young1,2, and
  7. Brian David Dynlacht3,6
  1. 1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA; 2Massachusetts Institute of Technology, Department of Biology, Cambridge, Massachusetts 02139, USA; 3Harvard University, Department of Molecular and Cellular Biology, Cambridge, Massachusetts 02138, USA

Abstract

The E2F transcription factor family is known to play a key role in the timely expression of genes required for cell cycle progression and proliferation, but only a few E2F target genes have been identified. We explored the possibility that E2F regulators play a broader role by identifying additional genes bound by E2F in living human cells. A protocol was developed to identify genomic binding sites for DNA-binding factors in mammalian cells that combines immunoprecipitation of cross-linked protein–DNA complexes with DNA microarray analysis. Among ∼1200 genes expressed during cell cycle entry, we found that the promoters of 127 were bound by the E2F4 transcription factor in primary fibroblasts. A subset of these targets was also bound by E2F1. Most previously identified target genes known to have roles in DNA replication and cell cycle control and represented on the microarray were confirmed by this analysis. We also identified a remarkable cadre of genes with no previous connection to E2F regulation, including genes that encode components of the DNA damage checkpoint and repair pathways, as well as factors involved in chromatin assembly/condensation, chromosome segregation, and the mitotic spindle checkpoint. Our data indicate that E2F directly links cell cycle progression with the coordinate regulation of genes essential for both the synthesis of DNA as well as its surveillance.

Keywords

Footnotes

  • 4 These authors contributed equally to this work.

  • 5 Present address: Ludwig Institute for Cancer Research, Department of Cellular and Molecular Medicine, University of California–San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA.

  • 6 Corresponding author.

  • E-MAIL dynlacht{at}biosun.harvard.edu; FAX (617) 496-1391.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.949802.

    • Received October 1, 2001.
    • Accepted November 16, 2001.
| Table of Contents

Life Science Alliance